A COVID-19 trial vaccine developed by the University of Oxford and AstraZeneca produced neutralizing antibody responses in patients with SARS-CoV-2, according to a study published July 20 in The Lancet. An immune response was detected in 32 of 35 participants after one dose and in all participants after a booster dose.

The trial will now proceed to phases two and three. Oxford/AstraZeneca in May announced it will provide the U.S. with 300 million initial doses and the U.K. 100 million initial doses this fall.

In a separate vaccine study by CanSino Biologics, also released today, a phase two test in Wuhan, China, showed an immunity response in 508 participants. The study said healthy adults may only need one dose, while older adults may need two to induce a better immune response. Results showed minimal adverse reactions; the candidate will now move to phase three testing.

Related News Articles

Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…